The FDA on July 30, 2019 approved NUBEQA® for non-metastatic Castration-Resistant Prostate Cancer (CRPC). NUBEQA® is a product of Bayer HealthCare Pharmaceuticals Inc.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement
Advertisement
The FDA on July 30, 2019 approved NUBEQA® for non-metastatic Castration-Resistant Prostate Cancer (CRPC). NUBEQA® is a product of Bayer HealthCare Pharmaceuticals Inc.
Advertisement